openPR Logo
Press release

Mantle Cell Lymphoma Treatment Market - Global Industry Insights 2025

02-05-2018 03:22 PM CET | Health & Medicine

Press release from: Pharmaceutical Report By CMI

Mantle Cell Lymphoma Treatment Market - Global Industry

Mantle cell lymphoma is a rare type of blood cancer, which occurs due to excessive growth of lymphocytes. Mantle cell lymphoma is one of the B-cell non-Hodgkin lymphoma, which occurs as a result of formation of tumors in the lymph nodes, which enters the blood and spreads to the bone marrow, digestive tract, spleen, and liver. Common symptoms of the disease include loss of appetite, weight loss, fever, nausea, and vomiting. The type of treatment for a patient suffering from mantle cell lymphoma depends on various factors such as the stage of disease, age, and overall health of the patient. In 2012, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for bortezomib (Velcade), which updates the existing label to include subcutaneous method of administration for the treatment of mantle cell lymphoma (MCL) patients who have received at least one prior therapy.

Rising prevalence of mantle cell lymphoma is expected to accelerate growth of the mantle cell lymphoma treatment market over the forecast period

Major factors driving growth of the mantle cell lymphoma market are rising prevalence of mantle cell lymphoma and increasing research and development activities in the healthcare sector resulting in a promising product pipeline. According to the study by Drug Development Technology, 2017, an estimated 3,300 new cases of mantle cell lymphoma are diagnosed every year in the U.S. The mantle cell lymphoma treatment market is expected to gain significant traction with the approval from the federal agencies. For instance, in October 2017, AstraZeneca received approval for Calquence under the FDA’s accelerated approval pathway for the treatment of adults with mantle cell lymphoma. Also, development of targeted agents with low toxicity profiles for the treatment of relapsed mantle cell lymphoma in combination with approved drugs is a major factor augmenting the mantle cell lymphoma treatment market growth. However, serious side effects of the drugs such as anemia, neutropenia, and diarrhea are the factors restraining growth of the mantle cell lymphoma treatment market.

Access Table of Content (TOC) Of the Report: https://www.coherentmarketinsights.com/ongoing-insight/toc/1148

The global mantle cell lymphoma treatment market is segmented on the basis of therapy type, route of administration, end user, and geography.

On the basis of therapy type, the global mantle cell lymphoma treatment market is segmented into:

Chemotherapy
Monoclonal Antibody Therapy
Targeted Therapy
Radiotherapy
Stem Cell Treatment

On the basis of route of administration, the global mantle cell lymphoma treatment market is segmented into:

Intravenous
Oral

On the basis of end user, the global mantle cell lymphoma treatment market is segmented into:

Hospitals
Clinics
Ambulatory Surgical Centers

Accelerated approval pathway program by the U.S. FDA is expected to propel the mantle cell lymphoma treatment market in North America

Regional segmentation of the mantle cell lymphoma treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be dominant in the global market over the forecast period. This is owing to increasing incidence rate of the disease in the region. According to the Leukemia and Lymphoma Society, 2014, about 70,800 new cases of cases of non-Hodkin Lymphoma were registered in the U.S., where mantle cell lymphoma represented about 6% or 4,200 cases of the total cases. Also, the FDA’s Center for Drug Evaluation and Research Agency works with manufacturers to analyze drug development, approval, promising the Breakthrough Therapy Destination Program to make treatments available for patients with rare disease. For instance, in 2013, the FDA approved Imbruvica (ibrutinib), manufactured by Janssen Pharmaceuticals, Inc. as a breakthrough therapy destination to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. Asia Pacific is expected to witness high growth rate in the mantle cell lymphoma treatment market over the forecast period owing to rising government initiatives, rise in research and development to curb the disease.

Click here to know more about this report: https://www.coherentmarketinsights.com/ongoing-insight/mantle-cell-lymphoma-treatment-market-1148

Key players operating the market include:

Key players are offering products to cater to unmet needs in patients with relapsed or refractory mantle cell lymphoma. For instance, Kite Pharma, Inc. is focused on developing engineered autologous T cell therapy products for the treatment of cancer. In 2015, the company initiated Phase 2 clinical study of KTE-C19 in patients with relapsed or refractory mantle cell lymphoma.

Key players operating in the global mantle cell lymphoma treatment market include F.Hoffman La Roche Ltd., Abbvie, Inc., Kite Pharma, Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc., and Johnson and Johnson.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Mantle Cell Lymphoma Treatment Market - Global Industry Insights 2025 here

News-ID: 931691 • Views: 214

More Releases from Pharmaceutical Report By CMI

Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the

All 5 Releases


More Releases for Mantle

Mantle Cell Lymphoma Treatment Market to See Incredible Growth By 2026
Mantle cell lymphoma is a rare type of blood cancer, which occurs due to excessive growth of lymphocytes. Mantle cell lymphoma is one of the B-cell non-Hodgkin lymphoma, which occurs as a result of formation of tumors in the lymph nodes, which enters the blood and spreads to the bone marrow, digestive tract, spleen, and liver. Common symptoms of the disease include loss of appetite, weight loss, fever, nausea, and
Global Mantle Cell Lymphoma Treatment Market Forecast Report 2018-2025 Bayer AG, …
A detailed market study on "Global Mantle Cell Lymphoma Treatment Market" examines the performance of the Mantle Cell Lymphoma Treatment market. It encloses an in-depth Research of the Mantle Cell Lymphoma Treatment market state and the competitive landscape globally. This report analyzes the potential of Mantle Cell Lymphoma Treatment market in the present and the future prospects from various angles in detail. The Global Mantle Cell Lymphoma Treatment Market 2018 report
Mantle Cell Lymphoma Treatment Market Predicted to Grow at a Moderate Pace Throu …
Mantle cell lymphoma is a rare type of blood cancer, which occurs due to excessive growth of lymphocytes. Mantle cell lymphoma is one of the B-cell non-Hodgkin lymphoma, which occurs as a result of formation of tumors in the lymph nodes, which enters the blood and spreads to the bone marrow, digestive tract, spleen, and liver. Common symptoms of the disease include loss of appetite, weight loss, fever, nausea, and
Global Mantle Cell Lymphoma Treatment Market Forecast 2018-2025 Celgene, Eisai, …
QYMarketStudy include new market study "Global Mantle Cell Lymphoma Treatment Market" examines the performance of the Mantle Cell Lymphoma Treatment market 2018. It encloses an in-depth Research of the Mantle Cell Lymphoma Treatment market state and the competitive landscape globally. This report analyzes the potential of Mantle Cell Lymphoma Treatment market in the present and the future prospects from various angles in detail. The Global Mantle Cell Lymphoma Treatment Market 2018
Mantle Cell Lymphoma Treatment Market : Industry Analysis, Opportunity Assessmen …
The latest market report published by Credence Research, Inc. “Mantle Cell Lymphoma Treatment Market - Growth, Future Prospects, Competitive Analysis, 2017 - 2025,” the global mantle cell lymphoma treatment market is set to grow at a CAGR of 4.8 % from 2017 to 2025. Browse the full report Mantle Cell Lymphoma Treatment Market - Growth, Future Prospects, Competitive Analysis, 2017 – 2025 at http://www.credenceresearch.com/report/mantle-cell-lymphoma-treatment-market Market Insights It is very important in patients suffering
Mantle Cell Lymphoma Treatment Market - Global Industry Insights, 2025
Mantle cell lymphoma is a rare type of blood cancer, which occurs due to excessive growth of lymphocytes. Mantle cell lymphoma is one of the B-cell non-Hodgkin lymphoma, which occurs as a result of formation of tumors in the lymph nodes, which enters the blood and spreads to the bone marrow, digestive tract, spleen, and liver. Common symptoms of the disease include loss of appetite, weight loss, fever, nausea, and